Lunit Inc.
Financials
Valuation Metrics
Lunit Inc.'s Market Cap is ₩7863B. At end of 2025 it was ₩1.4T. Ranked #354 of 2,433 in KR market (top 15%), #108 of 1,647 on KOSDAQ (top 7%), #10 of 96 in Health Care Equipment & Services (top 10%) by Market Cap.
Investment Metrics(as of 2026-08-14)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 786.28B KRW | KR#354/2,433 Sec#10/96 |
| Revenue | 91.82B KRW | KR#1,452/2,433 Sec#41/96 |
| Net Income | -55.82B KRW | KR—/2,433 Sec—/96 |
| Total Assets | 545.27B KRW | KR#716/2,433 Sec#11/96 |
| Net Assets | 331.64B KRW | KR#664/2,433 Sec#10/96 |
| Employees | 320 | KR#748/2,433 Sec#20/96 |
| Value | ||
| P/B | 2.37x | KR#2,005/2,433 Sec#71/96 |
| P/S | 8.56x | KR#2,253/2,433 Sec#81/96 |
| FCF Yield | -7.10% | KR—/2,433 Sec—/96 |
| Profitability | ||
| ROE | -16.83% | KR#2,047/2,433 Sec#73/96 |
| ROA | -10.24% | KR#2,105/2,433 Sec#72/96 |
| Op. Margin | -76.55% | KR#2,284/2,433 Sec#83/96 |
| Revenue Growth | 22.04% | KR#678/2,433 Sec#33/96 |
| Financial Health | ||
| Debt Ratio | 64.42% | KR#1,160/2,433 Sec#63/96 |
| Total Debt | 91.78B KRW | KR#708/2,433 Sec#14/96 |
| FCF | -55.81B KRW | KR#2,096/2,433 Sec#82/96 |
| Cash | 154.53B KRW | KR#332/2,433 Sec#3/96 |
| Performance | ||
| 1Y Return | -48.39% | KR#2,072/2,433 Sec#79/96 |
| 1M Return | 5.18% | KR#1,200/2,433 Sec#49/96 |
| From 52W High | -56.99% | KR#1,760/2,433 Sec#61/96 |
| 1Y MDD | -63.41% | KR#1,608/2,433 Sec#52/96 |
| Trading | ||
| Volume | 230,139 shares | KR#548/2,433 Sec#17/96 |
| Trading Value | 2.42B KRW | KR#563/2,433 Sec#13/96 |
| Foreign Own. | 12.06% | KR#392/2,433 Sec#13/96 |
| Per Share | ||
| EPS | -750 KRW | KR—/2,433 Sec—/96 |
| BPS | 4,454 KRW | KR#1,541/2,433 Sec#39/96 |
Company Info
Lunit, established in 2013 and headquartered in Gangnam-gu, Seoul, is a deep learning-based medical artificial intelligence enterprise that entered the U.S. market in 2024 through the acquisition of Volpara. The company develops cancer diagnostic image interpretation solution Lunit INSIGHT and biomarker solution Lunit SCOPE, offering product lines for cancer detection and treatment in chest X-rays and mammography. Lunit also expands its research and development and launches DBT products through partnerships with global manufacturers such as GE Healthcare.